High-throughput proteomics of breast carcinoma cells: a focus on FTICR-MS.
Discovery of better biomarkers for diagnosis, prognosis and therapy-response prediction is the most critical task of a scientific quest aimed at developing novel, tailormade therapies for patients with cancer. Consequently, a proteome-wide analysis, in addition to genomic studies, is an absolute requirement for a complete functional understanding of tumor biology. Ultra-sensitive, high-performance Fourier-transform ion-cyclotron resonance (FTICR) mass spectrometry (MS) currently holds an important role in fulfilling the demands of biomarker discovery. In this review, we describe the applicability of FTICR-MS for breast cancer proteomics, particularly for the analysis of complex protein mixtures obtained from a limited number of cells typically available from clinical specimens.
Umar
Arzu
A
University Medical Center Rotterdam, Josephine Nefkens Institute, Laboratory of Genomics & Proteomics in Breast Cancer, Department of Medical Oncology, Dr. Molewaterplein 50, Be 430c, PO Box 2040, 3000 CA, Rotterdam, The Netherlands. a.umar@erasmusmc.nl
Jaremko
Malgorzata
M
Burgers
Peter C
PC
Luider
Theo M
TM
Foekens
John A
JA
Pasa-Tolic
Ljiljana
L
D001943:Breast Neoplasms / Q000378:metabolism* / Q000473:pathology; D002851:Chromatography, High Pressure Liquid; D017357:Cyclotrons; D015180:Electrophoresis, Gel, Two-Dimensional; D005583:Fourier Analysis; D013058:Mass Spectrometry / Q000379:methods*; D040901:Proteomics